A novel trial design used mosinutuzumab monotherapy first in frontline follicular lymphoma, adding lenalidomide only for patients without a complete response. This adaptive approach successfully spared about two-thirds of patients from the added toxicities of lenalidomide while still achieving very high overall efficacy.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

A new agent, BGP-16673, works by destroying the BTK protein rather than just inhibiting it. This novel "degrader" mechanism is highly effective (75% response rate) in CLL patients who have developed resistance to covalent (e.g., ibrutinib), non-covalent (pirtobrutinib), and BCL-2 inhibitors, offering a new path for refractory disease.

The phase 3 INMIND trial showed adding tofacitimab to lenalidomide and rituximab (R-squared) significantly improves progression-free survival over R-squared alone. This fixed-duration regimen with a manageable toxicity profile is now considered a new standard of care for this patient population, including high-risk subsets.

The FLAIR trial provided the first clinical evidence that a time-limited combination of ibrutinib and venetoclax prevents the development of BTK resistance mutations. These mutations were observed in patients receiving continuous single-agent BTK inhibitor therapy, supporting a key theoretical advantage of time-limited combination approaches.

Current oral BTK/BCL-2 inhibitor combinations for CLL have hit an MRD clearance "wall" of 35-50%. By upgrading the BCL-2 inhibitor to the more potent somatoclax, combined with zanubrutinib, MRD clearance rates nearly double to 98%, demonstrating that improving the BCL-2 component is key to achieving deeper remissions.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

Subtle differences between second-generation BTK inhibitors like zanubrutinib and acalabrutinib lie in their pharmacokinetics. Zanubrutinib's ability to maintain drug concentration above the IC50 for the entire dosing interval may provide a theoretical advantage in highly proliferative disease by inhibiting newly synthesized BTK.

The ECHO trial's long-term follow-up demonstrates that adding acalabrutinib to BR chemotherapy in frontline MCL not only improves progression-free survival but also drastically reduces the need for subsequent therapy. This challenges the common clinical practice of reserving potent BTK inhibitors for later lines of treatment.